The primary therapeutic function of Dolargan (Pethidine/Meperidine) is to provide symptomatic support for significant, acute discomfort often associated with heightened symptom severity. The medicine is commonly applied in clinical settings that involve acute or unstable symptom patterns.

Dolargan is primarily relevant for managing moderate-to-severe pain that arises from medical events, procedures, or acute crises. It is used in conditions marked by episodic or fluctuating symptoms, including post-operative analgesia, support for conditions involving visceral pain (such as renal or biliary colic), and supportive care for obstetric analgesia during labor.

“The medicine is applied in scenarios where additional management of discomfort is required, and supports patients during episodes of heightened discomfort.”

This medication is utilized across domains where short-term symptomatic assistance is needed. Its general therapeutic benefit supports the patient during difficult episodes and plays a role in managing symptoms like postanesthetic shivering that create noticeable physiological strain during recovery.

---

Quick Fact: Symptom Management for Severe Discomfort

Who Can and Cannot Use Dolargan?

The use of Dolargan (Pethidine/Meperidine) is governed by strict population eligibility rules and contraindications defined by regulatory authorities.

Absolute Non-Eligibility (Contraindicated)

Dolargan is absolutely contraindicated in patients receiving Monoamine Oxidase Inhibitors (MAOIs) or who have stopped MAOIs within the past 14 days due to the risk of severe, potentially fatal reactions. It must also not be used in patients with significant respiratory depression, acute bronchial asthma in an unmonitored setting, or known gastrointestinal obstruction including paralytic ileus.

Restricted and Conditional Use

Eligibility is restricted based on age and organ function. Geriatric patients require extreme caution and a reduced starting dose due to the increased risk of neurotoxicity from the metabolite Normeperidine. Caution and often dose reduction are required for patients with renal impairment or hepatic impairment, as these conditions impair the clearance of Normeperidine. Use is typically not established or limited in pediatric patients under one year of age.

Pregnancy and Lactation

In pregnancy, prolonged use carries the risk of Neonatal Opioid Withdrawal Syndrome (NOWS). Pethidine is excreted in breast milk, requiring regulatory guidance to weigh the risk to the infant against the mother's clinical need.

Interactions with other medicines and products

The official regulatory profile for Pethidine (Dolargan) outlines strict prohibitions and cautions regarding its use with certain drug classes, driven by both pharmacodynamic (additive effects) and pharmacokinetic (altered exposure) interaction patterns.

Mandatory Contraindications and Timing Rules

• Monoamine Oxidase Inhibitors (MAOIs): Pethidine is formally contraindicated for use concurrently with or within 14 days of stopping an MAOI due to the risk of severe, unpredictable, and potentially fatal reactions, including coma and severe respiratory depression.

Clinically Significant Pharmacodynamic Interactions

• Central Nervous System (CNS) Depressants: Co-administration with CNS depressants, such as general anesthetics, benzodiazepines, and alcohol, is documented to result in the additive effect of profound sedation, life-threatening respiratory depression, coma, and death.
• Serotonergic Drugs: Use with drugs that affect the serotonergic system (e.g., SSRIs, SNRIs) is associated with the risk of developing Serotonin Syndrome.
• Mixed Opioid Analgesics: Combining Pethidine with mixed agonist/antagonist opioids (e.g., pentazocine, nalbuphine) may officially reduce the analgesic effect or precipitate withdrawal symptoms.

Pharmacokinetic Exposure Alterations

• CYP3A4 Inhibitors: The use of medicines that inhibit the CYP3A4 enzyme may increase meperidine plasma concentrations, which carries the risk of increased adverse reactions, including potentially fatal respiratory depression.
• Acyclovir and Cimetidine: These specific medicines are documented to alter Pethidine's clearance, which can result in increased plasma exposure of Pethidine or its active metabolite, normeperidine.

Population Note: Regulatory documents identify elderly, cachectic, or debilitated patients as being at increased risk for life-threatening respiratory depression from interactions with CNS depressants.

Dolargan, chemically pethidine (meperidine), acts primarily as an agonist at the mu-opioid receptor (MOR) located throughout the central and peripheral nervous systems. Binding to this G-protein coupled receptor (GPCR) subtype induces a conformational change, leading to the dissociation and activation of the inhibitory G-protein complex ( G i/ G o).

The activated G i/ G o complex modulates intracellular signaling pathways by inhibiting the enzyme adenylate cyclase. This inhibition results in a subsequent decrease in intracellular cyclic adenosine monophosphate (cAMP) concentrations. Concurrently, the activation of the receptor facilitates the opening of inwardly-rectifying potassium channels ( K^+ efflux) and inhibits presynaptic voltage-dependent calcium channels ( Ca^2+ influx).

These cellular effects—reduced cAMP, hyperpolarization via K^+ channel opening, and reduced Ca^2+ influx—collectively diminish neuronal excitability and decrease the release of numerous excitatory neurotransmitters from presynaptic nerve terminals, including Substance P, glutamate, and acetylcholine. This system-level modulation reduces signal transmission in ascending nociceptive pathways, primarily at the spinal cord and supraspinal levels. The agent may also exhibit secondary activity as an agonist at kappa-opioid receptors and as an inhibitor of the neuronal uptake of dopamine and norepinephrine, as well as binding to muscarinic receptors and sodium ion channels.

Dolargan, a solution containing Pethidine hydrochloride, is administered via Intramuscular (IM) injection, Subcutaneous (SC) injection, or slow Intravenous (IV) injection within a supervised clinical setting. The intramuscular route is generally preferred over the subcutaneous route for administration. The solution must be visually inspected for clarity before being prepared for use.

Official Dosing and Frequency

Standard dosing for acute, general analgesia in adults via IM or SC injection typically falls within the range of 50 mg to 100 mg per single dose. For slow intravenous administration, a lower dose, such as 25 mg to 50 mg, is commonly used and must be administered slowly. Doses for obstetric analgesia are also typically 50 mg to 100 mg. The maximum total dose must not exceed established limits, such as 600 mg over a 24-hour period.

The medicine is administered on an as-needed (PRN) basis for acute pain. Single doses should not be repeated more often than every three to four hours. This frequency aligns with the drug’s intended use for intermittent, acute pain episodes.

Adjustments and Duration

Dose adjustments are required for specific patient populations. Lower initial doses and/or extended dosing intervals are necessary for older adults and patients with documented renal or hepatic impairment. Furthermore, the therapy is intended strictly for short-term use, often limited to 48 hours or less, consistent with acute management protocols.

Dolargan: Recent Clinical Evidence

Evidence for Acute, Severe Pain Management

Dolargan was studied for managing outcomes related to physical discomfort, particularly in patients experiencing conditions associated with acute or disruptive episodes, such as pain following surgery. The research examined short-term Randomized Controlled Trials (RCTs) and systematic reviews, comparing Pethidine against inactive treatment or other common analgesics. Research examined whether the use of the medicine was observed to coincide with changes in patient-reported pain scores; comparative studies reported varying measurements. The evidence is confined to acute, short-term settings, typically tracking pain measurements only for the first few hours post-injection. Long-term outcomes reflecting daily functioning are not well characterized, and research provides limited insight into how symptoms change over extended periods.

Evidence for Analgesia During Labor

Clinical research has explored the use of Dolargan in women during labor, a context relevant in trials assessing short-term or episodic symptom patterns. These studies included short-term RCTs, applied in studies examining patient-reported experiences of maternal comfort, and researchers also examined outcomes for the newborn. Findings indicate that studies report changes in pain intensity and moderate levels of maternal satisfaction. However, the overall certainty remains low because the evidence quality varies across studies and is frequently described as low or very low in systematic reviews, limiting insight into outcomes related to systemic imbalance.

Evidence for Managing Postanesthetic Shivering

Dolargan was evaluated in research exploring temporary physiological imbalance, specifically exploring shivering that was associated with the recovery period following general or spinal anesthesia. Comparative trials reported measurements related to the cessation and prevention of postanesthetic shivering. The findings describe patterns related to the measured physiological responses, but results apply only to the populations studied during the acute recovery period.

Research Gaps and Uncertainty

The clinical evaluation is consistently relevant only in trials assessing short-term changes. Limited information for long-term outcomes exists regarding the durability of relief. Furthermore, data for certain groups, such as pediatric or older populations, remain insufficient within the existing research base. Sample sizes were modest in many reviewed trials, and comparative evidence is lacking consistency across all indications, indicating that more comprehensive investigation is needed to fill these knowledge gaps.

Key Studies & References

1. Criteria for Use of Meperidine - VA.gov

Common questions about Dolargan (FAQ)

---

Q: What is the chemical or classification difference between Dolargan and morphine?

Dolargan (Pethidine/Meperidine) is classified as a fully synthetic opioid. Official sources describe it as belonging to the phenylpiperidine chemical class. This is chemically distinct from morphine, which is derived from natural opiate alkaloids.

---

Q: What is the typical duration of pain relief expected from one dose of Dolargan?

According to official product information, the pain relief from an injection is relatively short-acting. The typical duration of effective pain relief lasts between 1 to 3 hours.

---

Q: What is serotonin syndrome and how is the risk related to Dolargan?

Serotonin syndrome is a serious condition linked to dangerously high levels of serotonin in the brain. Regulatory warnings associated with this medicine outline that symptoms may include confusion, agitation, high fever, sweating, muscle twitching, or diarrhea. This risk is primarily a concern when Dolargan is used with other medicines that also increase serotonin levels.

---

Q: Why is Dolargan discouraged for treating long-term or chronic pain conditions?

The official label discourages the use of Dolargan for long-term or chronic pain management. This is because extended use increases the risk of toxicity, which may include seizures. This heightened risk is linked to the body’s inability to clear the drug’s active metabolite, normeperidine, which can accumulate over time.

---

Q: How is Dolargan classified by government drug agencies, such as in the US or UK?

Government agencies, such as the U.S. Drug Enforcement Administration, classify Dolargan (Meperidine) as a Schedule II controlled substance. This regulatory classification acknowledges the drug's accepted medical use while recognizing its high potential for abuse and severe physical dependence.

---

Q: Is Dolargan available to children, and are there different safety guidelines for them?

Official regulatory information states that the safety and effectiveness of Dolargan have not been established across the entire pediatric population. Official product information indicates that use requires caution and is determined based on body weight.

---

Q: How quickly does the pain relief from Dolargan usually start working?

Because Dolargan is administered via injection, the onset of pain relief is generally fast. Clinical data indicates that the pain-relieving effects usually begin quickly, typically within 3 to 6 minutes after administration.

---

Q: Can Dolargan be taken with common over-the-counter pain relievers like Tylenol or Aleve?

In clinical settings, the medication is often used alongside non-opioid pain relievers like acetaminophen or ibuprofen as part of a broader pain management strategy. However, patients should check with a healthcare professional regarding combining medications, especially to ensure they do not exceed the maximum daily limit for acetaminophen.

---

Q: What are the signs of physical dependence on Dolargan?

Physical dependence is a normal biological adaptation the body undergoes with repeated use of an opioid. This is demonstrated by the occurrence of withdrawal symptoms if the drug is suddenly reduced or stopped. These symptoms may include anxiety, muscle aches, insomnia, sweating, and a runny nose.

---

Q: Is Dolargan considered a first-line or second-line treatment for acute pain?

Regulatory guidance indicates that Dolargan is not considered a first-line therapy for acute pain. It is generally reserved for patients for whom alternative treatment options, such as non-opioid analgesics, have been tried and were found to be inadequate or not tolerated.

---

Q: Why might the body develop a tolerance to the effects of Dolargan over time?

Tolerance is a natural biological consequence of repeated opioid exposure, causing a reduced response over time that may require a higher dose for the same effect. Official medical literature explains this happens because the body’s opioid receptors (the proteins the drug binds to) adapt and become desensitized.

---

Q: Why is Dolargan used less often now than it was 20 years ago?

The frequency of this medicine's use in clinical practice has declined due to recognized safety concerns. This is primarily related to the risk of neurotoxicity—effects like seizures or delirium—caused by the drug's metabolite, normeperidine, which can accumulate in the body.

---

Q: What is the meaning of the REMS program associated with this type of pain medicine?

The REMS (Risk Evaluation and Mitigation Strategy) program is a regulatory requirement established by the FDA. Its purpose is to ensure that the known and potential serious risks of a medicine, such as this potent opioid, are managed to ensure its benefits continue to outweigh its risks.

---

Q: What is the difference between physical dependence and addiction regarding Dolargan?

According to authoritative health literature, physical dependence is a normal biological adaptation that results in withdrawal symptoms if the drug is suddenly stopped. Addiction (also known as Opioid Use Disorder) is a chronic disease characterized by a compulsive use of the drug and a loss of control over that use, despite it causing harm.

---

Q: Is Dolargan listed on the World Health Organization's List of Essential Medicines?

No, Dolargan (Pethidine/Meperidine) is not currently included on the World Health Organization's Model List of Essential Medicines. The medicine was formally removed from this list in 2003.

Storage and Handling Requirements

Dolargan (Meperidine) must be stored under specific conditions to maintain its stability and to comply with regulatory security mandates for this controlled substance.

Scope Item	Official Regulatory Requirement
Storage Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Excursions are permitted between 15 C and 30 C [2.3].
Environmental Protection	Keep from freezing and store away from light and excess moisture [1.4]. Keep the container tightly closed [1.2].
Stability After Opening	Multiple-dose vials: Discard unused portion after 28 days. Single-dose products: Discard any unused portion immediately after use [2.3].
Child Safety	The medicine must be kept out of the sight and reach of children and stored in a safe, secured place to prevent accidental ingestion or theft [1.1, 1.4].

Official Disposal Instructions

Disposal must occur immediately for unused, unwanted, or expired Dolargan due to its high risk of harm from accidental ingestion.

• Preferred Method: The product must be disposed of using an authorized drug take-back program or DEA-registered collector [3.7].
• Flushing: If a take-back option is not promptly available, the FDA directs that Meperidine should be flushed down the toilet. This is an exception made for high-risk opioids where the danger of accidental exposure outweighs environmental concern [2.5, 3.6].
• Packaging: Scratch out all personal information on the prescription label before discarding the empty container [1.5].

Connection to the overall storage/disposal profile: Regulatory documents define the storage profile by mandating specific temperature control and protection from light and freezing to ensure product quality. Due to the high-risk nature of this potent opioid, the profile is further structured by strict security requirements and a specific, expedited disposal protocol to eliminate the risk of accidental exposure.